AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer - Results of two parallel first-in-human phase I studies

A. Omlin, R. J. Jones, R. Van Der Noll, T. Satoh, M. Niwakawa, S. A. Smith, J. Graham, M. Ong, R. D. Finkelman, J. H M Schellens, A. Zivi, M. Crespo, R. Riisnaes, D. Nava-Rodrigues, M. D. Malone, C. Dive, R. Sloane, D. Moore, J. J. Alumkal, A. DymondP. A. Dickinson, M. Ranson, G. Clack, J. De Bono, T. Elliott*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Fingerprint

Dive into the research topics of 'AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer - Results of two parallel first-in-human phase I studies'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science